We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

164 hedge funds and large institutions have $274M invested in Heron Therapeutics in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 50 increasing their positions, 46 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,362% more call options, than puts

Call options by funds: $4.21M | Put options by funds: $171K

56% more capital invested

Capital invested by funds: $176M → $274M (+$98.7M)

33% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 18

6.34% more ownership

Funds ownership: 75.57% → 81.91% (+6.3%)

2% more funds holding

Funds holding: 161 → 164 (+3)

9% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 46

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
164
Holders Change
+3
Holders Change %
+1.86%
% of All Funds
2.2%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
24
Increased
50
Reduced
46
Closed
18
Calls
$4.21M
Puts
$171K
Net Calls
+$4.04M
Net Calls Change
-$511K

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.74M
2
ACM
AIGH Capital Management
Maryland
+$5.39M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.3M
4
PCM
Palisade Capital Management
New Jersey
+$2.64M
5
Millennium Management
Millennium Management
New York
+$2.29M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$1.67M
2
CC
Clearline Capital
New York
-$1.46M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.43M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.26M
5
OCM
Orchard Capital Management
Illinois
-$863K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCMNY
1
Rubric Capital Management (New York)
New York
$58.8M – – –
BlackRock
2
BlackRock
New York
$18.8M -$53K -27,323 -0.3%
Vanguard Group
3
Vanguard Group
Pennsylvania
$18.1M +$132K +67,976 +0.8%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$17.3M -$1.26M -648,000 -8%
VCIM
5
Velan Capital Investment Management
Georgia
$15.4M – – –
PCM
6
Palisade Capital Management
New Jersey
$11.6M +$2.64M +1,360,542 +35%
Point72 Asset Management
7
Point72 Asset Management
Connecticut
$10.5M +$3.3M +1,700,068 +55%
TC
8
Tejara Capital
United Kingdom
$10.1M -$163K -84,140 -2%
State Street
9
State Street
Massachusetts
$7.16M +$209K +107,711 +3%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$6.85M +$191K +98,401 +3%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$6.61M +$5.74M +2,958,497 +6,407%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$6.57M -$1.43M -737,509 -20%
ACM
13
AIGH Capital Management
Maryland
$6.11M +$5.39M +2,778,200 New
JAM
14
JW Asset Management
Florida
$5.14M +$88K +45,325 +2%
Renaissance Technologies
15
Renaissance Technologies
New York
$5M +$2.11M +1,085,700 +91%
TCM
16
Tang Capital Management
California
$4.92M +$185K +95,188 +4%
CPC
17
Congress Park Capital
New York
$4.48M -$815K -419,878 -17%
Morgan Stanley
18
Morgan Stanley
New York
$4.25M -$1.67M -860,785 -31%
New York State Common Retirement Fund
19
New York State Common Retirement Fund
New York
$3.86M +$838K +431,918 +33%
OCM
20
Orchard Capital Management
Illinois
$3.15M -$863K -444,702 -24%
Millennium Management
21
Millennium Management
New York
$3.07M +$2.29M +1,179,754 +547%
Marshall Wace
22
Marshall Wace
United Kingdom
$2.76M +$460K +237,157 +23%
Charles Schwab
23
Charles Schwab
California
$2.4M -$31.7K -16,354 -1%
CC
24
Clearline Capital
New York
$2.33M -$1.46M -750,572 -41%
Two Sigma Investments
25
Two Sigma Investments
New York
$2.32M +$122K +62,812 +6%
1
2 3 4 5

HRTX Hedge Fund Activity: Q1 2025 in Review

164 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2025, worth a combined $274M — up 56% from $176M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new HRTX positions and 18 closed out — a net gain of 6 holders — while 50 added to existing stakes and 46 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $5.74M. The largest seller was Morgan Stanley, cutting an estimated $1.67M.

  • 164 institutional investors held Heron Therapeutics (HRTX) as of Q1 2025, up from 161 in Q4 2024.
  • Funds reported $274M of Heron Therapeutics stock for Q1 2025, up 56% quarter-over-quarter.
  • 24 funds opened new Heron Therapeutics positions in Q1 2025 and 18 closed out, a net change of +6 holders.
  • The largest Heron Therapeutics buyer in Q1 2025 was T. Rowe Price Associates, an estimated $5.74M added.
  • The largest Heron Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $1.67M sold.

Based on aggregated 13F filings for Q1 2025.